Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23173884 | 0.93 | MAOB (0.53) | MAOBCYP2C9CYP2C19SMN1; SMN2MAPT | |
| SCHEMBL12659906 | 0.89 | CYP2C9 (0.56) | MAOBCYP2C9CYP2C19SMN1; SMN2MAPT | |
| SCHEMBL6448598 | 0.89 | SMN1; SMN2 (0.56) | MAOBCYP2C9CYP2C19SMN1; SMN2MAPT | |
| SCHEMBL24227092 | 0.89 | MAOB (0.62) | MAOBCYP2C9CYP2C19SMN1; SMN2MAPT | |
| SCHEMBL383618 | 0.88 | FOLH1 (0.58) | CYP2C9CYP2C19SMN1; SMN2L3MBTL1MRGPRX4 | |
| SCHEMBL29660966 | 0.87 | MAOB (0.53) | MAOBCYP2C9CYP2C19SMN1; SMN2MAPT | |
| SCHEMBL22918087 | 0.87 | MAOB (0.53) | MAOBCYP2C9CYP2C19SMN1; SMN2MAPT | |
| SCHEMBL4140081 | 0.87 | MAOB (0.67) | MAOBCYP2C9CYP2C19SMN1; SMN2MAPT | |
| SCHEMBL2469286 | 0.87 | MRGPRX4 (0.52) | CYP2C9CYP2C19SMN1; SMN2MRGPRX4KDM4E | |
| SCHEMBL21327265 | 0.86 | ALDH1A1 (0.56) | CYP2C9CYP2C19SMN1; SMN2MRGPRX4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | THE INSTITUTE OF CANCER RESEARCH (GB) | 2019-09-17 | — | — | US | disclosed |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | THE INSTITUTE OF CANCER RESEARCH (GB) | 2019-09-17 | — | — | US | disclosed |
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-31 | — | — | US | disclosed |
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | disclosed |
| EP-3248968-A1 | RESORCINOL DERIVATIVE AS HSP90 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2017-11-29 | — | — | EP | disclosed |
| US-20170326152-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-11-16 | — | — | US | disclosed |
| US-20170326152-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-11-16 | — | — | US | disclosed |
| WO-2006109075-A2 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006109085-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| US-20060148817-A1 | Pyrazole compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1567151-B1 | 3-(2-HYDROXY-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | VERNALIS CAMBRIDGE LTD (GB) | 2006-03-15 | — | — | EP | disclosed |
| EP-1611112-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | Vernalis (Cambridge) Limited (GB) | 2006-01-04 | — | — | EP | disclosed |
| EP-1572664-A1 | PYRAZOLE COMPOUNDS | Vernalis (Cambridge) Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| EP-1567151-A1 | 3-(2-HYDROXY-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | Vernalis (Cambridge) Limited (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004072051-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004056782-A1 | PYRAZOLE COMPOUNDS | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004050087-A1 | 3-(2-HYDROXY-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | HSP90AB1, HSP90AA1, HSP90AB2P | MAOB 3850/4885CYP2C9 1489/4885CYP2C19 878/4885 |
| US-20170326152-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | HSP90AB1, HSP90AA1, HSP90AB2P | MAOB 3440/4885CYP2C9 1533/4885CYP2C19 2136/4885 |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | MAOB 3368/4885CYP2C9 1538/4885CYP2C19 2156/4885 |
| US-20060148817-A1 | Pyrazole compounds | NRAS, HSP90AB1, HSP90AA1 | MAOB 2878/4885CYP2C9 1053/4885CYP2C19 1426/4885 |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | MAOB 3440/4885CYP2C9 1533/4885CYP2C19 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.